| 87.49 0.79 (0.91%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 109.87 | 1-year : | 128.33 |
| Resists | First : | 94.06 | Second : | 109.87 |
| Pivot price | 86.92 |
|||
| Supports | First : | 83.28 | Second : | 76.62 |
| MAs | MA(5) : | 85.26 |
MA(20) : | 86.14 |
| MA(100) : | 73.71 |
MA(250) : | 72.3 |
|
| MACD | MACD : | 1.8 |
Signal : | 2.4  |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 23.7 |
| RSI | RSI(14): 59.5 |
|||
| 52-week | High : | 107.37 | Low : | 47.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACLX ] has closed below upper band by 43.3%. Bollinger Bands are 9.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88.58 - 88.89 | 88.89 - 89.17 |
| Low: | 84.65 - 85.04 | 85.04 - 85.4 |
| Close: | 86.86 - 87.41 | 87.41 - 87.92 |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Mon, 27 Oct 2025
symbol__ Stock Quote Price and Forecast - CNN
Tue, 21 Oct 2025
Arcellx, Inc. (ACLX) Investor Outlook: Exploring A 30% Upside In Biotech Innovation - DirectorsTalk Interviews
Fri, 17 Oct 2025
Arcellx Inc (ACLX) Has a New Rating from Stifel Nicolaus - The Globe and Mail
Fri, 10 Oct 2025
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook - Yahoo Finance
Mon, 06 Oct 2025
Arcellx (NASDAQ:ACLX) Biggest Nasdaq Stocks Mirror Biotech Progress - Kalkine Media
Mon, 06 Oct 2025
Arcellx CFO Gilson sells $511k in ACLX stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 105.9 (%) |
| Shares Short | 6,260 (K) |
| Shares Short P.Month | 6,730 (K) |
| EPS | -3.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.07 |
| Profit Margin | 0 % |
| Operating Margin | -777.5 % |
| Return on Assets (ttm) | -19.8 % |
| Return on Equity (ttm) | -42.8 % |
| Qtrly Rev. Growth | -72.5 % |
| Gross Profit (p.s.) | -2.08 |
| Sales Per Share | 1.02 |
| EBITDA (p.s.) | -3.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -118 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -25.66 |
| PEG Ratio | 0 |
| Price to Book value | 12.35 |
| Price to Sales | 85.15 |
| Price to Cash Flow | -41.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|